Activates B lymphocytes and enhanced immune response : A promising adjuvant based on PLGA nanoparticle to improve the sensitivity of ZEN monoclonal antibody
Copyright © 2024 Elsevier B.V. All rights reserved..
In preparing monoclonal antibodies by hybridoma cell technology, the quality of B lymphocytes used for cell fusion directly affects the sensitivity of monoclonal antibodies. To obtain B-lymphocytes producing high-quality specific antibodies for cell fusion during the immunization phase of the antigen, we prepared a TH2-Cell stimulatory delivery system as a novel adjuvant. Astragalus polysaccharide has a good ability to enhance antigenic immune response, and it was encapsulated in biocompatible materials PLGA as an immunostimulatory factor to form the delivery system (APS-PLGA). The preparation conditions of APSP were optimized using RSM to attain the highest utilization of APS. Immunization against ZEN-BSA antigen using APSP as an adjuvant to obtain B lymphocytes producing ZEN-specific antibodies for cell fusion. As results present, APSP could induce a stronger TH2 immune response through differentiating CD4 T cells and promoting IL-4 and IL-6 cytokines. Moreover, it could slow down the release efficiency of ZEN-BSA and enhance the targeting of ZEN-BSA to lymph nodes in vivo experiments. Ultimately, the sensitivity of mouse serum ZEN-specific antibodies was enhanced upon completion of immunization, indicating a significant upregulation of high-quality B lymphocyte expression. In the preparation of monoclonal antibodies, the proportion of positive wells for the first screening was 60%, and the inhibition rates of the antibodies were all similar (>50%). Then we obtained the ZEN monoclonal antibody with IC50 of 0.049 ng/mL, which was more sensitive than most antibodies prepared under conventional adjuvants. Finally, a TRFIAS strip assay was preliminarily established with a LOD value of 0.246 ng/mL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:274 |
|---|---|
| Enthalten in: |
Talanta - 274(2024) vom: 09. Apr., Seite 126005 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pang, Chengchen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant |
|---|
| Anmerkungen: |
Date Revised 10.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.talanta.2024.126005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370884396 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370884396 | ||
| 003 | DE-627 | ||
| 005 | 20240411233122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.talanta.2024.126005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM370884396 | ||
| 035 | |a (NLM)38599116 | ||
| 035 | |a (PII)S0039-9140(24)00384-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pang, Chengchen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Activates B lymphocytes and enhanced immune response |b A promising adjuvant based on PLGA nanoparticle to improve the sensitivity of ZEN monoclonal antibody |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a In preparing monoclonal antibodies by hybridoma cell technology, the quality of B lymphocytes used for cell fusion directly affects the sensitivity of monoclonal antibodies. To obtain B-lymphocytes producing high-quality specific antibodies for cell fusion during the immunization phase of the antigen, we prepared a TH2-Cell stimulatory delivery system as a novel adjuvant. Astragalus polysaccharide has a good ability to enhance antigenic immune response, and it was encapsulated in biocompatible materials PLGA as an immunostimulatory factor to form the delivery system (APS-PLGA). The preparation conditions of APSP were optimized using RSM to attain the highest utilization of APS. Immunization against ZEN-BSA antigen using APSP as an adjuvant to obtain B lymphocytes producing ZEN-specific antibodies for cell fusion. As results present, APSP could induce a stronger TH2 immune response through differentiating CD4 T cells and promoting IL-4 and IL-6 cytokines. Moreover, it could slow down the release efficiency of ZEN-BSA and enhance the targeting of ZEN-BSA to lymph nodes in vivo experiments. Ultimately, the sensitivity of mouse serum ZEN-specific antibodies was enhanced upon completion of immunization, indicating a significant upregulation of high-quality B lymphocyte expression. In the preparation of monoclonal antibodies, the proportion of positive wells for the first screening was 60%, and the inhibition rates of the antibodies were all similar (>50%). Then we obtained the ZEN monoclonal antibody with IC50 of 0.049 ng/mL, which was more sensitive than most antibodies prepared under conventional adjuvants. Finally, a TRFIAS strip assay was preliminarily established with a LOD value of 0.246 ng/mL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adjuvant | |
| 650 | 4 | |a Astragalus polysaccharide | |
| 650 | 4 | |a Enhancement of the TH2 immune response | |
| 650 | 4 | |a PLGA | |
| 650 | 4 | |a TRFICA | |
| 650 | 4 | |a ZEN monoclonal antibody | |
| 700 | 1 | |a Yuan, Bei |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Keyun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Haitao |e verfasserin |4 aut | |
| 700 | 1 | |a Nie, Kunying |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Chunlei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhanli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yanyan |e verfasserin |4 aut | |
| 700 | 1 | |a Ozkan, Sibel A |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qingqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Talanta |d 1966 |g 274(2024) vom: 09. Apr., Seite 126005 |w (DE-627)NLM114409137 |x 1873-3573 |7 nnns |
| 773 | 1 | 8 | |g volume:274 |g year:2024 |g day:09 |g month:04 |g pages:126005 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.talanta.2024.126005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 274 |j 2024 |b 09 |c 04 |h 126005 | ||